Surgical interventions incurred higher total costs than pharmacotherapy, primarily due to substantial direct medical costs associated with LSG. Pharmacotherapy exhibited relatively higher direct non-medical costs, and indirect costs were a notable contributor across all interventions. These findings shed light on the economic burden of obesity and advocate for further exploration of costs related to lifestyle modifications and long-term assessments. The data supports future cost-effectiveness studies, aiding decision-making in obesity management.
Sharif et al. (Thu,) studied this question.